TELOMERE: Phase 1/2 Investigator-Sponsored Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia
TELOMERE is a Phase 1/2 clinical trial evaluating imetelstat in patients with relapsed/refractory acute myeloid leukemia, or AML. The trial is designed to test two distinct combinations of imetelstat and venetoclax or imetelstat and azacitidine. The primary objective of the Phase 1 portion is to identify the safe dose of each of the combinations. Up to 20 patients are expected to be enrolled into this portion of the TELOMERE study.
The primary objective of the Phase 2 portion of the study is overall response rate for each of the combination regimens. We expect the trial to start in the first half of 2022.